The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients
The Oncologist · 2025
DOI: 10.1093/oncolo/oyae279 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Amr Radwan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology and Medical Oncology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA 02118, United Sta…. Hauptthemen laut MEDLINE: Black or African American, Carcinoma, Non-Small-Cell Lung, Drug-Related Side Effects and Adverse Reactions, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Introduction
The development of immune-related adverse events (irAEs) has been associated with improved survival outcomes in non-small cell lung cancer (NSCLC). However, this association’s extent across race and ethnicity remains uncertain. We evaluated the association between the development of irAEs and treatment outcomes across racially diverse groups treated at a safety net hospital.
Methods
A retrospective chart review was performed to identify patients with advanced NSCLC treated between 2015 and 2020. The incidence of irAEs across racial subgroups was compared using logistic regression analysis. Cox regression analysis was performed to evaluate the association between the development of irAEs and treatment outcomes.
Results
We identified 138 NSCLC patients treated with immune checkpoint inhibitors (ICIs), of whom 50% identified as non-Hispanic Black (NHB). Incidence of irAEs was 28%, with no significant difference between NHB and other racial groups. However, females [OR 2.3, 95% CI, (1.1-4.8)] and patients with Medicaid or MassHealth insurance had a higher incidence of irAEs [OR 2.7 (1.2-5.7)]. Additionally, patients with irAEs had a lower risk of disease progression (multivariable HR 0.46, 95% CI, 0.23-0.92) compared to those without irAEs. The association between irAEs and improved progression free survival (PFS) in NHB patients was similar to the other racial group [median PFS 246 vs 181 days; HR 0.87 (0.58-1.29)].
Conclusion
We demonstrated a similar incidence of irAEs in NHB patients with NSCLC as compared to other racial groups. Patients who developed irAEs experienced significantly improved survival outcomes. This association remained independent of race and ethnicity, underscoring the importance of providing unbiased treatment recommendations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Hematology and Medical Oncology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, MA 02118, United States.
- Department of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33166, United States.
- Department of Pulmonary and Critical Care, Temple University, Philadelphia, PA 19140, United States.
- Boston University School of Public Health, Boston, MA 02118, United States.
- Department of Medicine, Beth Israel Deaconess Medical Center, MA 02215, United States.
- Division of Graduate Medical Sciences, Boston University Chobanian and Avedisian School of Medicine, MA 02118, United States.
ORCID-Profile: Amr Radwan, Chinmay T Jani, Umit Tapan
Zitieren
APA
Radwan, A., Jani, C. T., Al Omari, O., Patel, M., Burns, L., Mackay, Z., Li, L., Mahdaviani, K., Davidson, A., Weinberg, J., Everett, P. C., Suzuki, K., Mak, K. S., Kulke, M. H., & Tapan, U. (2025). The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients. The Oncologist. https://doi.org/10.1093/oncolo/oyae279
Vancouver
Radwan A, Jani CT, Al Omari O, Patel M, Burns L, Mackay Z, et al. The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients. The Oncologist. 2025. doi:10.1093/oncolo/oyae279
BibTeX
@article{Radwan2025,
author = {Radwan, Amr and Jani, Chinmay T and Al Omari, Omar and Patel, Mohini and Burns, Laura and Mackay, Zoe and Li, Liuping and Mahdaviani, Kiana and Davidson, Arielle and Weinberg, Janice and Everett, Peter C and Suzuki, Kei and Mak, Kimberley S and Kulke, Matthew H and Tapan, Umit},
title = {The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyae279}
}
EUVIMED